Company intelligence / Profile preview
CSL Seqirus
Holly Springs, North Carolina, USAcslseqirus.com ↗
- Ownership
- Public · CSL
- Employees
- ~3000
- Development stage
- Commercial
01
Overview
CSL Seqirus is one of the world’s largest manufacturers of influenza vaccines with commercialized products distributed in over twenty countries. The company leverages egg-based, cell-culture–based, and adjuvanted technologies to offer a broad portfolio of seasonal and pandemic flu vaccines. Real-world evidence supports their effectiveness across age groups including high-risk populations such as older adults. In addition to flu vaccines, they supply antivenoms and Q fever vaccine primarily within Australia/New Zealand.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Inactivated influenza vaccines (egg-based and cell-based)Adjuvanted vaccinesRecombinant protein vaccines (limited pipeline)Antivenoms and specialty biologics in Australia/New Zealand
- Industry
- Pharma
02
Drug pipeline
124 assets123 more assets in the full pipeline.
03
Partnerships
Collaborates with global public health agencies/governments on pandemic preparednesspartnerships with WHO/international health authorities for surveillance/vaccine strain selection.
04
Financials
- Market cap
- $66.7B
- Total revenue
- $16B
- Enterprise value
- $76.1B
Beyond the preview
Go deeper on CSL Seqirus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL Seqirus.